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The effects of a chimeric monoclonal antibody (chA6 mAb) that recognizes both the RO and 
RB isoforms of the transmembrane protein tyrosine phosphatase CD45 on human T cells 
were investigated. Chimeric A6 (chA6) mAb potently inhibited antigen-specific and 
polyclonal T cell responses. ChA6 mAb induced activation-independent apoptosis in 
CD4
 
 
 
CD45RO/RB
 
high
 
 T cells but not in CD8
 
 
 
 T cells. In addition, CD4
 
 
 
 T cell lines specific for 
tetanus toxoid (TT) generated in the presence of chA6 mAb were anergic and suppressed the 
proliferation and interferon (IFN)-
 
 
 
 production by TT-specific effector T cells by an 
interleukin-10–dependent mechanism, indicating that these cells were equivalent to type 1 
regulatory T cells. Similarly, CD8
 
 
 
 T cell lines specific for the influenza A matrix protein-
derived peptide (MP.58-66) generated in the presence of chA6 mAb were anergic and 
suppressed IFN-
 
 
 
 production by MP.58-66–specific effector CD8
 
 
 
 T cells. Furthermore, 
chA6 mAb significantly prolonged human pancreatic islet allograft survival in nonobese 
diabetic/severe combined immunodeficiency mice injected with human peripheral blood 
lymphocytes (hu-PBL-NOD/SCID). Together, these results demonstrate that the chA6 mAb is 
a new immunomodulatory agent with multiple modes of action, including deletion of 
preexisting memory and recently activated T cells and induction of anergic CD4
 
 
 
 and CD8
 
 
 
 
regulatory T cells.
 
The transmembrane protein tyrosine phos-
phatase (PTPase) CD45 plays a critical role in
lymphocyte activation. Alternative splicing of
exons 4–6 generates eight different CD45 iso-
forms in humans which differ in the size of their
extracellular domains while sharing identical
cytoplasmic PTPase domains (1). Although the
function of the extracellular domain of each
CD45 isoform remains to be defined, it is well
established that the cytoplasmic PTPase domain
acts as a positive regulator of T cell receptor–
mediated signaling, which is essential for activa-
tion and development of lymphocytes (2).
Individual lymphocytes simultaneously
express multiple isoforms of CD45 (1, 3).
However, the highest, intermediate, and low-
est molecular weight isoforms recognized by
CD45RABC-, CD45RB-, and CD45RO-
specific mAbs, respectively, are differentially
expressed on T and B cells as well as on func-
tionally different subsets of CD4
 
 
 
 T cells
(4–6). In mice, mAbs recognizing CD45RB
isoforms are used to differentiate two popula-
tions of CD4
 
 
 
 T cells, CD4
 
 
 
CD45RB
 
high
 
 and
CD4
 
 
 
CD45RB
 
low
 
 (5, 6), that secrete different
cytokines and have distinct functional proper-
ties. The CD4
 
 
 
CD45RB
 
high
 
 population con-
tains effector T cells, which have been shown to
induce autoimmunity (7) or inflammatory bowel
disease (8), whereas the CD4
 
 
 
CD45RB
 
low
 
 pop-
ulation contains regulatory T (T reg) cells, which
prevent the induction of T cell–mediated dis-
eases (8) including acute allograft rejection (9).
Several studies demonstrated that a mAb
specific for the CD45RB isoform is a potent
immunomodulator that prolongs allograft sur-
vival in several murine transplantation models
(10–14) and induces long-term engraftment
and donor-specific tolerance in murine renal
and islet allografts (11, 13). The exact mecha-
 
CORRESPONDENCE
Maria Grazia Roncarolo: 
m.roncarolo@hsr.it
 
Abbreviations used: 
 
  
 
m, value 
of change in mitochondria 
transmembrane potential; chA6, 
chimeric A6; MLP, mixed lym-
phocyte-peptide; MP, matrix 
protein-derived peptide; PTPase, 
protein tyrosine phosphatase; 
T reg, regulatory T; TT, tetanus 
toxoid. 
IMMUNOMODULATORY EFFECTS OF AN ANTIHUMAN CD45RO/RB 
 
M
 
AB | Gregori et al.
 
1294
 
nism underlying tolerance mediated by anti-CD45RB mAb
is still unclear. It has been suggested that anti-CD45RB mAb
interferes with T cell activation and causes a shift toward the
expression of the low isoform (CD45RB
 
low
 
) on CD4
 
 
 
T cells (10–12, 15). This inversion of the CD45RB
 
high
 
/
CD45RB
 
low
 
 T cell subset ratio is caused by selective deple-
tion of CD45RB
 
high
 
 effector cells after in vivo treatment
with anti-CD45RB mAb (16).
The mouse anti–human mAb A6 has a unique specificity
and recognizes both the RO and RB isoforms of CD45 on
human cells (17). It has been shown that in vitro depletion
of A6
 
 
 
 cells from PBMCs dramatically decreased prolifera-
tion and cytotoxic activity of these cells in response to recall
and alloantigens or anti-CD3 mAb stimulation (17). In the
present study, we investigated the immunomodulatory prop-
erties of a chimeric A6 (chA6) mAb in which constant
mouse regions of A6 mAb were substituted by human con-
stant regions of human IgG1/
 
 
 
 isotype. Our results demon-
strate that chA6 mAb is a potent immunomodulator that in-
hibits responses of both primary and preactivated T cells,
selectively mediates apoptosis of CD4
 
 
 
CD45RO/RB
 
bright
 
 T
cells, and induces populations of CD4
 
 
 
 and CD8
 
 
 
 T reg
cells in vitro. In addition, chA6 mAb mediates long-term
survival of human pancreatic islet allograft in hu-PBL-
NOD/SCID mice.
 
RESULTS
ChA6 mAb inhibits T cell proliferation
 
It has been shown that some mAbs that bind to the
CD45RB isoform are capable of selectively inhibiting both
mouse and human T cell responses (18–20). We investigated
the effect of chA6 mAb, which specifically recognizes the
CD45RO and CD45RB isoforms, on the proliferative re-
sponses of human CD4
 
 
 
 T cells following stimulation with
anti-CD3 mAb, alloantigens, or tetanus toxoid (TT). ChA6
mAb inhibited the proliferation of CD4
 
 
 
 T cells activated
with immobilized anti-CD3 mAb. The strongest inhibition
was observed at anti-CD3 mAb concentrations of 0.01 
 
 
 
g/
ml (81 
 
 
 
 13%; 
 
n
 
 
 
 
 
 4; P 
 
 
 
 0.05), whereas at concentrations
of 0.1 
 
 
 
g/ml the inhibition was 45 
 
 
 
 23% (P 
 
 
 
 0.05). No
significant inhibition (4 
 
 
 
 0.5%) was observed at 1-
 
 
 
g/ml
concentrations of anti-CD3 mAb. Comparable inhibitory
effects were obtained when T cells were stimulated with
anti-CD3 and anti-CD28 mAbs. The strongest inhibition
(86 
 
 
 
 12%; 
 
n 
 
 
 
 4, P 
 
 
 
 0.05) was observed at anti-CD3
mAb concentrations of 0.01 
 
 
 
g/ml, whereas inhibitions of
49 
 
 
 
 24% and 24 
 
 
 
 18% were obtained at anti-CD3 mAb
concentrations of 0.1 
 
 
 
g/ml and 1 
 
 
 
g/ml, respectively (Fig.
1 A). The inhibitory effect of chA6 mAb was dose-depen-
dent: the percentages of inhibition of T cells activated with
anti-CD3 mAb (0.01 
 
 
 
g/ml) were 71 
 
 
 
 10% (
 
n
 
 
 
 
 
 2, P 
 
 
 
0.03), 66 
 
 
 
 5% (
 
n
 
 
 
 
 
 2, P 
 
 
 
 0.01), and 42 
 
 
 
 22% (
 
n
 
 
 
 
 
 2,
P 
 
 
 
 0.03) at concentrations of 10, 1, and 0.1 
 
 
 
g/ml of chA6
mAb, respectively. Comparable dose-dependent inhibitory
effects were observed on T cells activated with 0.1 
 
 
 
g/ml of
anti-CD3 mAb. Under these conditions, inhibitions of 55 
 
 
 
12% (
 
n
 
 
 
 
 
 3, P 
 
 
 
 0.001), 35 
 
 
 
 6% (
 
n
 
 
 
 
 
 3, P 
 
 
 
 0.01), 35 
 
 
 
12% (
 
n
 
 
 
 
 
 3, p-value was not significant) were obtained at
concentrations of 10, 1, and 0.1 
 
 
 
g/ml of chA6 mAb, re-
spectively (Fig. 1 B). These data indicate that the strongest
inhibition of proliferation is observed when T cells are acti-
vated with low concentrations of anti-CD3 mAb (0.01 
 
 
 
g/
ml) and optimal doses of chA6 mAb (10 
 
 
 
g/ml). This inhi-
bition is reproducible and specific, because it is not observed
in the presence of a chimeric control mAb.
ChA6 mAb also inhibited proliferation of CD4
 
 
 
 T cells
in primary (mean inhibition, 57 
 
 
 
 17%; 
 
n
 
 
 
 
 
 14, P 
 
 
 
 0.02)
and secondary MLRs (Fig. 2 A). In the latter case, a mean
inhibition of 30 
 
 
 
 16% (
 
n
 
 
 
 
 
 4, P 
 
 
 
 0.05) was observed
when CD4
 
 
 
 T cells, primed with allogeneic APC for 10 d
without chA6 mAb, were restimulated with the original al-
logeneic cells in the presence of chA6 mAb (Fig. 2 A). As
expected, chA6 mAb inhibited the proliferation of CD4
 
 
 
 T
cells stimulated with allogeneic APC in a dose-dependent
fashion: 41 
 
 
 
 18% (
 
n
 
 
 
 
 
 5, P 
 
 
 
 0.04), 37 
 
 
 
 18% (n   5,
P   0.03), and 33   9% (n   5, p-value was not signifi-
cant.) inhibition was obtained at concentrations of 10, 1, and
0.1  g/ml of chA6 mAb, respectively (Fig. 2 A). No inhibi-
tion was observed when cells were cultured in the presence
of a chimeric isotype control mAb.
Figure 1. ChA6 mAb inhibits polyclonal proliferation of CD4  
T cells. (A) CD4  T cells were stimulated with the indicated concentrations 
of coated anti-CD3 mAb in the presence or absence of chA6 or chimeric 
isotype control mAb (10  g/ml) with or without soluble anti-CD28 mAb 
(1  g/ml). Results from one representative donor out of four are shown. 
(B) Dose-dependent inhibition of proliferative polyclonal T cell response by 
chA6 mAb. CD4  T cells were stimulated with 0.1 and 0.01  g/ml of 
coated anti-CD3 mAb in the presence of the indicated concentrations of 
soluble chA6 mAb. Results from one representative donor out of three 
(0.1  g/ml of anti-CD3 mAb) and out of two (0.01  g/ml of anti-CD3 
mAb) are shown. The percentages of inhibition of proliferation in the 
presence of chA6 mAb relative to control are indicated.JEM VOL. 201, April 18, 2005 1295
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Finally, chA6 mAb also inhibited TT-specific memory T
cell responses. A mean inhibition of 47   24% (n   16, P  
0.02) of the proliferative responses of PBMCs stimulated
with TT was observed (Fig. 2 B). Taken together, these data
indicate that chA6 mAb inhibits primary, secondary, and
memory T cell proliferative responses.
ChA6 mAb induces apoptosis in A6brightCD4  T cells
To determine whether the inhibition of proliferation was
caused by depletion of responder T cells, the ability of chA6
mAb to induce T cell apoptosis was investigated. Overnight
incubation of CD4  T cells with chA6 mAb in the presence
or absence of anti-CD3 and anti-CD28 mAb resulted in in-
creased percentages of early apoptotic (annexin V /PI )
cells. The percentages of annexin V /PI  cells were signifi-
cantly higher in cultures incubated with 10  g/ml or 1  g/
ml of chA6 mAb (38   13% and 30   11%, respectively;
n   20, P   0.005) than in cultures incubated with an iso-
type control mAb (20   9%) (Fig. 3 A). The mean value of
ED50 for the induction of apoptosis was 20.6   8.7  g/ml
(Fig. 3 B). Apoptosis induced by chA6 mAb was not signifi-
cantly enhanced when CD4  T cells were activated with
anti-CD3 and anti-CD28 mAbs (Fig. 3 A). Double staining
of CD4  T cells with annexin V–FITC and A6-PE mAb re-
vealed that apoptosis was induced mainly in CD4 A6bright
cells (Fig. 3 C), which represent the CD45RO/RBbright cells
(not depicted; reference 17). These results indicate that chA6
mAb induces apoptosis in CD4  T cells in a dose-dependent
manner, which does not require T cell activation, and selec-
tively depletes CD4 CD45RO/RBbright T cells, which rep-
resent the CD4  effector/memory T cell population.
Cross-linking of CD45RO or CD45RA isoforms by
specific mAb did not induce apoptosis on human CD4  T
cells (Fig. 3 D), indicating the specific effect of the cross-link
of CD45RO/RB isoform by chimeric A6 mAb. ChA6 mAb
failed to induce apoptosis of CD8  T cells and of non–T
cells at concentrations up to 10  g/ml, indicating a specific
effect on CD4  T cells (unpublished data).
To verify whether the apoptosis mediated by chA6 mAb
was targeting preexisting CD4 A6bright responding T cells,
we examined the effect of chA6 mAb on cells preincubated
with chA6 mAb and depleted of annexin V  cells. As ex-
pected, depletion of annexin V  cells resulted in a reduced
percentage of CD4 A6bright T cells, whereas the proportion
of CD4 A6low T cells increased (unpublished data). Annexin
V–depleted CD4  T cells reexpressed the A6 epitope on the
cell surface (not depicted) and subsequently became suscepti-
ble to apoptosis induced by chA6 mAb (Fig. 3, A and C).
Together, these data show that ligation of CD45RB/RO
isoforms by chA6 mAb leads to the death of preexisting and
de novo induced CD4 A6bright memory T cells. The obser-
vation that chA6 mAb inhibited primary allogeneic prolifer-
ative responses of freshly isolated CD4  T cells (mean value
of inhibition, 46   22%; n   4, P   0.005) and annexin V–
depleted CD4  T cells (mean value of inhibition, 53   21%;
n   4, P   0.05) in a comparable fashion (Fig. 3 E) indicates
that the immunosuppressive effect of chA6 mAb is caused by
the induction of apoptosis of preexisting CD4 A6bright T
cells and of newly activated effector cells, which expressed
the A6 epitope at high levels.
ChA6 mAb induces apoptosis through the intrinsic pathway
We investigated the mechanism involved in the apoptosis
induced by chA6 mAb by analyzing the expression and acti-
vation of several caspases, including caspase-3, one of the
key molecules involved in apoptosis. The p17 active subunit
Figure 2. ChA6 mAb inhibits allogeneic and TT-specific prolifera-
tion of CD4  T cells. (A) Primary MLR: CD4  T cells were stimulated with 
allogeneic CD3-depleted cells with or without chA6 mAb (10  g/ml). Results 
from one representative donor out of 14 are shown. Secondary MLR: CD4  T 
cells were primed with allogeneic CD3-depleted cells for 10 d. Cells were 
collected and washed, and proliferative responses to the same allogenic 
cells used in the primary stimulation in the presence or absence of chA6 
mAb (10  g/ml) were tested. Results from one representative donor out of 
four are shown. Dose-dependent inhibition of primary MLR: CD4  T cells 
were stimulated with allogeneic CD3-depleted cells in the presence of the 
indicated concentrations of chA6 or chimeric isotype control mAbs. Results 
from one representative donor out of five are shown. R, responder; S, 
stimulator. (B) TT response: total PBMCs were stimulated with TT with or 
without chA6 mAb (10  g/ml). Results from one representative donor out 
of 16 are shown. The percentages of inhibition of proliferation in the 
presence of chA6 mAb relative to control are indicated.IMMUNOMODULATORY EFFECTS OF AN ANTIHUMAN CD45RO/RB MAB | Gregori et al. 1296
Figure 3. Dose-dependent apoptosis induced in CD4 A6bright T cells 
by chA6 mAb. (A) CD4  T cells were incubated with the indicated con-
centrations of chA6 or isotype control mAbs. Cells were cultured overnight 
without (unstimulated) or with (stimulated) coated anti-CD3 (0.1  g/ml) 
and soluble anti-CD28 (1  g/ml) mAb and were analyzed for apoptosis. 
The percentages of early apoptotic (annexin V /PI ) cells and mean   SE 
are shown. P values were calculated by t test: *P, effect of chA6 mAb on 
total CD4  T cells; $P, effect on annexin V–depleted CD4  T cells (*P or
$P   0.05; **P   0.005). (B) PBMCs of three healthy donors were cultured 
overnight in the presence of the indicated concentrations of chA6 mAb 
(filled symbols) or an IgG1 isotype control antibody (open symbols) and 
analyzed for apoptosis. Curve fitting and ED50 value calculations were per-
formed. (C) Total or annexin V–depleted CD4  T cells were incubated with 
the indicated concentrations of chA6 mAb. Cells were cultured overnight 
without or with (stimulated) coated anti-CD3 (0.1  g/ml) and soluble 
anti-CD28 (1  g/ml) mAbs and were stained with annexin V FITC mAb and 
chA6 mAb followed by anti-human IgG1PE mAb and analyzed by flow 
cytometry. Percentages of positive cells, set according to the isotype-
matched controls (not shown), are shown in the top corner of the quadrant. 
Results from one representative out of 10 different donors tested are 
shown. (D) CD4  T cells were incubated with the indicated concentrations 
of anti-CD45RO (UCLH-1), anti-CD45RA (HI-100), chA6, or isotype control JEM VOL. 201, April 18, 2005 1297
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of caspase-3 was expressed in CD4  T cells cultured with
chA6 alone, indicating that ligation of CD45RO/RB results
in activation of the caspase cascade and induction of cell
death in unstimulated CD4  T cells. As expected, the p17
subunit was expressed in CD4  T cells activated with anti-
CD3 and anti-CD28 mAbs in the presence or absence of
chA6 mAb (Fig. 4 A). Next we investigated the processing
and expression of caspase-8 and caspase-9 in CD4  T cells
treated with chA6 mAb to determine whether chA6 mAb
induces apoptosis through the activation of the death recep-
tors CD95 and TNF-R, which requires caspase-8 (21), or by
direct activation of the intrinsic apoptotic pathway, which
requires activation of caspase-9 (22). As shown in Fig. 4 A,
the full-length protein (p57) and the cleavage products (p43/
p41) of caspase-8 were detected in all conditions tested,
whereas the p18 active subunit of caspase-8 was not de-
tected. Conversely, both the full-length protein (p46) and
the cleaved active forms (p37/35) of caspase-9 were detected
in CD4  T cell cultured with chA6 mAb.
One of the first events required for induction of apoptosis
via caspase-9 is perturbation of the mitochondria that results in
the release of cytochrome c and proapoptotic factors and ulti-
mately in caspase-9 activation (23). The mitochondrial accu-
mulation of DiOC6(3) was used to assess the value of change
in the mitochondria transmembrane potential (  m) (24) in
CD4  T cells treated with chA6 mAb. No   m was ob-
served in medium or isotype control mAb-treated CD4  T
cells (Fig. 5 B), whereas   m was significantly reduced in
CD4  T cells incubated with chA6 mAb. Together, these re-
sults indicate that chA6 mAb–induced apoptosis of CD4  T
cells is caused by triggering of the intrinsic pathway and is in-
dependent from CD95 and TNF-R receptor/ligation.
ChA6 mAb modulates antigen-specific CD4  T cell responses
Although apoptosis of CD4  T cells may contribute to the
antiproliferative effects of chA6 mAb, chA6 mAb inhibited
both polyclonal and alloantigen-induced proliferation of T
cells at concentrations of 0.1  g/ml, which failed to induce
significant apoptosis in CD4  T cells (Figs. 1–3).
To determine further whether chA6 mAb, in addition to
its apoptotic effect on T effector cells, also has immunomod-
ulatory effects, induction of antigen-specific anergic T reg
cells was investigated. Total PBMCs were activated with TT
in the presence (TT/chA6) or absence (TT) of chA6 mAb.
After two rounds of stimulation under the same conditions,
CD4  T cell lines were rechallenged with TT in the absence
of chA6 mAb. Results shown in Fig. 5 A demonstrate that
chA6 mAb induced a profound state of unresponsiveness in
TT-specific CD4  T cells. Both proliferation (mean value of
inhibition, 72   28%; n   18, P   0.03) and IFN-  pro-
duction (mean value of inhibition, 91   10%; n   10, P  
0.027) were strongly inhibited. The unresponsiveness was
dependent on TCR activation because TT and TT/chA6
cell lines produced comparable levels of IFN-  in response
to activation by 12-0-tetradecanoylphorbol-13-acetate and
ionomycin (n   3, P   0.1) (Fig. 5 A).
To determine whether anergic TT/chA6 cell lines con-
tain T reg 1 cells, TT-specific effector CD4  T cell lines
generated as described previously were rechallenged with
TT and autologous APC in the presence of increasing num-
bers of anergic TT/chA6 cells. Results shown in Fig. 5 B
mAbs. Cells were stimulated with coated anti-CD3 (0.1  g/ml) and soluble 
anti-CD28 (1  g/ml) mAbs, cultured overnight, and analyzed for apopto-
sis. The percentages of early-apoptotic (annexinV /PI ) cells are shown. 
(E) Total or annexin V–depleted CD4  T cells were stimulated with alloge-
neic CD3-depleted cells with or without chA6 mAb (10  g/ml). Results 
from one representative donor out of four are shown. The percentages of 
inhibition of proliferation in the presence of chA6 mAb relative to control 
are presented.
Figure 4. ChA6 mAb induce apoptosis in CD4  T cells through the 
activation of the intrinsic pathway. (A) CD4  T cells were incubated 
with the indicated concentrations of chA6 mAb. Cells were cultured over-
night with or without coated anti-CD3 (0.1  g/ml) and soluble anti-CD28 
(1  g/ml) mAbs. Western blot tests with anti-caspase-3, anti-caspase-8, 
and anti-caspase-9 mAb were performed. As positive control, Hela cells 
were treated with staurosporine, 5  M. Amounts of loaded proteins have 
been controlled for homogeneity by probing membranes with an anti-
 -actin mAb. Weak expression of the cleavage products of caspase-9 in 
CD4  T cells cultured in medium is considered background apoptosis. 
Results from one representative donor out of three are shown. (B) CD4  T 
cells were incubated with chA6 mAb (5  g/ml) in the presence of 15  g/ml 
of cross-linking goat anti–human IgG (F(ab )2). Mitochondrial-based death 
pathways were assessed using 3,3 -dihexyloxacarbocyanine iodide (DiOC6(3)) 
accumulation that reflects changes in   m in the mitochondria. Results 
from one representative donor out of three are shown.IMMUNOMODULATORY EFFECTS OF AN ANTIHUMAN CD45RO/RB MAB | Gregori et al. 1298
demonstrate that anergic TT/chA6 cells suppressed the IFN- 
production of effector TT-specific CD4  T cells in a dose-
dependent manner (mean value of inhibition, 41   15%
at 1:2 ratio, P   0.03; 33   11% at 1:1 ratio, P   0.02; and
21   12% at 1:0.5 ratio in four donors tested).
TT/chA6 cell lines and control TT cell lines contained
comparable percentages of CD4  T cells expressing CD25,
but the percentages of CD4  T cells expressing CD69 was
reduced (n   10, P   0.03; Fig. 6 A). This reduction re-
sulted in lower percentages of CD25 CD69  T cells in an-
ergic TT/chA6 cell lines as compared with TT control cell
lines. CTLA-4, GITR, and FOXP3 mRNA expression was
similar in the anergized and nonanergized TT cell lines (un-
published data). From these data it can be concluded that
TT-specific suppressor T cell lines generated in the presence
of chA6 mAb did not contain higher proportion of CD4 
CD25  T reg cells.
The overall number of cytokines produced by anergized
TT/chA6 cell lines was low. After antigen-specific activa-
tion, these anergized T cells did not produce IL-2 and IL-4
and secreted significantly lower amounts of IFN-  than did
nonanergized control cells (Fig. 5 A and not depicted).
However, the amounts of IL-10 were significantly higher
than those produced by nonanergized control cells, 277  
54 pg/ml versus 147   60 pg/ml (n    4, P   0.004),
whereas the levels of TGF-  were not significantly different
(Fig. 6 B). Thus, TT-specific T cell lines generated in the
presence of chA6 mAb display a profile of cytokine produc-
tion similar to that of T reg 1 cells (25).
Reversal of suppression of both proliferation (not de-
picted) and IFN-  production (Fig. 6 C) was observed when
a neutralizing anti–IL-10R mAb was added to the cultures,
demonstrating that suppression by TT/chA6 cells is medi-
ated by IL-10. Together, these data indicate that repetitive
Figure 5. ChA6 mAb induced TT-specific CD4  T reg cells. (A) Total 
PBMCs were stimulated with TT with or without chA6 mAb (10  g/ml). 
TT-specific cell lines were rechallenged with TT-pulsed and nonpulsed 
autologous irradiated monocytes in the absence of chA6 mAb. Results 
from one representative donor out of 18 are shown. The percentage of 
inhibition of proliferation in the presence of chA6 mAb relative to control 
is presented. Alternative: after 48 h culture, IFN-  was quantified in culture 
supernatants by ELISA. Results from one representative donor out of 
10 are shown. The percentage of inhibition of IFN-  release in the 
presence of chA6 mAb relative to control is shown. Iono, ionomycin; TPA, 
12-0-tetradecanoylphorbol-13-acetate. (B). TT-specific cell lines were 
cocultured with increased amounts of TT-specific T cell lines generated in 
the presence of chA6 mAb (TT/chA6) and stimulated with TT-pulsed and 
nonpulsed autologous irradiated monocytes in the absence of chA6 mAb. 
After 48 h of culture, IFN-  was quantified in culture supernatants by 
ELISA. Results from one representative donor out of four are shown. The 
percentages of inhibition of proliferation in the presence of chA6 mAb 
relative to control are presented.
Figure 6. ChA6 mAb induced TT-specific CD4  T reg 1 cells. (A) TT-
specific cell lines were stained with the indicated surface molecules and 
analyzed by flow cytometry with gating on live CD4  T cells. Thin lines 
represent staining with the appropriate control mAbs. Results from one 
representative donor out of 10 are shown. (B) TT and TT/chA6 cell lines 
were stimulated with TT-pulsed autologous irradiated monocytes in the 
absence of chA6 mAb. Supernatants were collected after 72 h, and levels 
of IL-10 and TGF-  were determined by ELISA. (C) TT cell lines were cocul-
tured with TT/chA6 cell lines (1:1 ratio) and stimulated with TT-pulsed and 
nonpulsed autologous irradiated monocytes in the presence of 10  g/ml 
of anti–IL-10R mAb. After 48 h culture, IFN-  was quantified in culture 
supernatants by ELISA. Results from one representative donor out of two 
are shown. The percentage of inhibition of IFN-  release in the presence 
of chA6 mAb relative to control is presented.JEM VOL. 201, April 18, 2005 1299
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stimulation of CD4  T cells with TT in the presence of
chA6 mAb leads to the induction of T reg cells that are phe-
notypically and functionally equivalent to T reg 1 cells.
ChA6 mAb modulates antigen-specific CD8  T cell responses
To test whether chA6 mAb could also modulate antigen-spe-
cific CD8  T cells, PBMCs from HLA-A*0201 individuals
were stimulated in a mixed lymphocyte-peptide (MLP)–spe-
cific reaction with an immunodominant influenza A ma-
trix  protein-derived peptide (MP.58-66) in the presence
(MLPchA6) or in the absence (MLP) of chA6 mAb. After
two rounds of stimulation, MLP cultures were rechallenged
with MP.56-88 in the absence of chA6 mAb. MLPchA6 cells
were far less responsive to antigen stimulation than were their
MLP counter parts, as demonstrated by the reduced produc-
tion of IFN-  in response to MP.58-66 (mean value of inhi-
bition, 59   30%; n   16, P   0.02; Fig. 7 A). Furthermore,
CD8  T cells generated in the presence of chA6 mAb dis-
Figure 7. ChA6 mAb induced MP.58-66–specific CD8  T reg cells. 
(A) Enriched CD8  T cells were stimulated with 10  g/ml peptide MP.58-66, 
in the absence (MLP) or presence of 10  g/ml chA6 mAb (MLPchA6). After 
two rounds of stimulation, MLP and MLPchA6 cells were rechallenged 
with T2 cells previously pulsed with the MP.58-66 peptide. After 24 h 
culture, IFN-  was quantified in culture supernatants by ELISA. Results 
from one representative donor out of 16 are shown. The percentage of 
inhibition of IFN-  release in the presence of chA6 mAb relative to control 
is presented. (B) MLP and MLPchA6 cells were stained with TCR-V 17–
specific mAb. Results from one representative out of eight donors tested 
are shown. (C) After two rounds of stimulation, MLP cells were cocultured 
with increased amounts of MLPchA6 cells with MP.56-88 pulsed and non-
pulsed T2 cells in the absence of chA6 mAb. After 24 h culture, IFN-  was 
quantified in culture supernatants by ELISA. Results from one representa-
tive out of three donors tested are shown. The percentage of inhibition of 
IFN-  release in the presence of chA6 mAb relative to control is presented. 
(D) MP.58-66–specific T cell lines were stained with the indicated surface 
molecules and analyzed by flow cytometry. Percentages of positive cells, 
set according to the isotype controls, are shown in the relative quadrant. 
Results from one representative donor out of four donors tested are 
shown. (E) MLP cells were cocultured with MLPchA6 cells (1:1 ratio) and 
stimulated with MP.56-88 pulsed and nonpulsed APC in the presence of 
10  g/ml anti-IL-10R and 10  g/ml anti-TGF-  mAb. After 24 h of cul-
ture, IFN-  was quantified in culture supernatants by ELISA. Results from 
one representative out of two donors tested are shown. The percentages 
of inhibition of IFN-  release in the presence of chA6 mAb relative to 
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played lower antigen-specific cytotoxic activity than did con-
trol CD8  T cells (unpublished data). MP.58-66–specific
CD8  T effector cells can be monitored by staining with a
mAb recognizing TCR V 17, the dominant V  chain used
by these cells (26). The percentages of MP.58-66–specific
V 17 CD8  T cells in chA6-anergized and control cultures
were comparable (Fig. 7 B), indicating that MP.58-66–spe-
cific CD8  T cells were not deleted during stimulation in the
presence of chA6 mAb but instead became functionally inac-
tivated. We next investigated whether MP.58-66–specific
CD8  T cells generated in the presence of chA6 mAb have
suppressive activity. MP.58-66–specific effector CD8  T cells
were rechallenged with APC, pulsed with MP.58-66, in the
presence of increasing number of MLPchA6 cells. MLPchA6
cells inhibited IFN-  production by MLP-specific effector
CD8  T cells in a dose-dependent fashion (mean value of in-
hibition, 42   19% at 1:2 ratio; 23   9% at 1:1 ratio; and
15   8% at 1:0.5 ratio in three donors tested; Fig. 7 C).
The percentages of MP.58-66–specific CD8  T cells ex-
pressing CD25 were reduced in MLPchA6 cultures as com-
pared with MLP cultures (n   4, P   0.01) (Fig. 7 D), indi-
cating that CD8 CD25  T reg cells were not responsible for
the reduced IFN-  production by MLPchA6 cells. In addi-
tion, the reduced percentage of MP.58-66–specific CD8  T
cells expressing CD69 in MLPchA6 cultures supports the
conclusion that antigen-specific CD8  T cells generated
Figure 8. ChA6 mAb treatment prolongs human islet allograft sur-
vival in hu-PBL-NOD/SCID recipient mice. (A) Diabetic NOD/SCID mice 
were transplanted under the kidney capsule with human islets. Mice were 
injected intraperitoneally with 50   106 allogeneic human PBMCs. Normal 
NOD/SCID mice (*, n   8) were used as control of human islets function. 
Mice were treated with vehicle ( , n   12); with the Edmonton protocol 
( , n   4); chA6 mAb at days 0, 3, and 5 after transplantation ( , n   14); 
or sirolimus ( , n   3). Glycemia levels monitored graft survival. Asterisks 
indicate statistical analysis in which treated mice were compared with 
control mice (***   0.0001). (B) Kidney bearing the human-islet graft from 
control, chA6 mAb–treated, or normal NOD/SCID mice at 100 d after 
transplantation were snap-frozen, and 5- m-thick sections were stained 
with hematoxylin and eosin (HE). Alternatively, sections were stained for 
the expression of CD3 and insulin.JEM VOL. 201, April 18, 2005 1301
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with chA6 mAb remain functionally inactivated. Both MLP
and MLPchA6 cultures expressed comparable levels of CD28,
excluding the possibility that MP.58-66–specific CD8  T
reg cells generated in the presence of chA6 mAb contained
CD8 CD28  suppressor T cells.
The overall cytokine levels (IL-2, IL-4, IL-10, and TGF- )
produced after antigen-specific stimulation by MP.58-66–
specific CD8  T cell lines was below the detection level
(unpublished data). However, the suppression mediated by
anergic MLPchA6 cells was partially reversed by neutralizing
anti-TGF-  and anti–IL-10R mAbs (Fig. 7 E), suggesting that
chA6 mAb induces antigen-specific CD8  T reg cells that
have a mode of action similar to that of CD4  T reg 1 cells.
ChA6 mAb prolongs human islet allograft survival 
in NOD/SCID mice
To determine whether chA6 mAb also exert immunomodu-
latory effects in vivo, we established a modified model of hu-
man islet transplantation in NOD/SCID mice. Human islets
were transplanted under the kidney capsule of NOD/SCID
mice rendered diabetic by a single injection of streptozotocin.
NOD/SCID recipient mice were injected intraperitoneally
with freshly isolated allogeneic PBMCs. Hu-PBL-NOD/
SCID recipient mice were treated with chA6 mAb at 1 mg/
kg subcutaneously at days 0, 3, and 5 after transplantation.
Normal NOD/SCID mice transplanted with human islets re-
mained normoglycemic up to 100 d after transplantation,
whereas the mean rejection time of hu-PBL-NOD/SCID
mice transplanted with human islets was 35   13 d. The short
treatment of transplanted hu-PBL-NOD/SCID mice with
chA6 mAb significantly prolonged the survival of human islets
(survival rate of  70% at day 60 and of 50% at day 100 after
transplantation; Fig. 8 A). Comparison of the in vivo effect of
chA6 mAb with sirolimus and with a combined immunosup-
pressive therapy (sirolimus, tacrolimus, and anti-IL2R  mAb
anti-TAC) defined as the Edmonton protocol (27) clearly
demonstrated that a short treatment with chA6 mAb is signif-
icantly more effective that monotherapy with sirolimus but
less powerful than the Edmonton protocol in preventing al-
lograft rejection in hu-PBL-NOD/SCID mice. (Fig. 8 A).
Histological analyses of human islet grafts performed 100 d af-
ter transplantation showed a massive infiltration of human
CD3 , CD4 , and CD8  T cells (Fig. 8 B and not depicted)
in control mice. In contrast, significantly lower numbers of
infiltrating cells were observed in mice treated with chA6
mAb (Fig. 8 B and not depicted). The staining for insulin was
similar in hu-PBL-NOD/SCID–recipient mice treated with
chA6 mAb and in transplanted mice not injected with PB-
MCs, demonstrating the graft function. Collectively, these
data indicate that a short treatment with chA6 mAb prolongs
human islet allograft survival in vivo.
DISCUSSION
In the present study, we analyzed the immunomodulatory
effects of a chimeric A6 mAb that has unique specificity and
recognizes both the RB and RO isoforms of CD45 on hu-
man cells (17). We demonstrated that chA6 mAb suppresses
T cell responses in vitro through several mechanisms: inhibi-
tion of proliferation of primary, activated, and memory T
cells; induction of apoptosis in effector/memory CD4 
CD45RO/RBbright T cells; and generation of antigen-spe-
cific T reg cells in both the CD4  and CD8  T cell subsets.
Moreover, administration of chA6 mAb prolongs human is-
let allograft survival in hu-PBL-NOD/SCID mice.
Several studies demonstrated that CD45 RO- and RB-
specific mAbs inhibit proliferative primary responses of T
cells in humans (13, 18, 19) and mice (20). Here, we show
that chA6 mAb inhibits not only primary polyclonal and al-
loantigen-specific T cell responses but also secondary and
memory responses, indicating that chA6 mAb has a broad
and powerful suppressive effect on T cell proliferation.
Induction of apoptosis in human T cells (28, 29) and
murine thymocytes by ligation of CD45 has been described
(30). It has been shown that cell death induced by cross-
linking of CD45 in human T and B cells resembles cell death
induced by CD95 (29), indicating that in human cells liga-
tion of CD45 induces apoptosis via the extrinsic pathway.
On the other hand, apoptosis of murine T lymphocytes in-
duced by CD45 cross-linking resulted in a rapid increase in
  m that was not inhibited by caspase inhibitors (30), indi-
cating the use of the intrinsic apoptotic pathway. Similarly,
anti-CD45RB mAb induced a rapid elimination of both
murine CD4  and CD8  T cells in vitro caused by mito-
chondrial-dependent cell death mechanisms (16). Interest-
ingly, the apoptotic effects induced by CD45 ligation in mu-
rine T lymphocytes was independent of the PTPase activity
of the CD45 molecules, indicating a crucial role of the ex-
tracellular domain of the CD45 (28). Here, we show that
CD45RB/RO ligation induces selective cell death in hu-
man CD4  T cells through a CD95-independent mecha-
nism. This effect is specific for the chA6 mAb, because it was
not observed with anti-CD45RA and anti-CD45RO mAbs.
Apoptosis induced by chA6 mAb is mediated via the intrin-
sic pathway, as demonstrated by the presence of caspase-9–
and -3–activated subunits and by the reduction in mito-
chondrial transmembrane potential which occurs 2 h after
CD45RB/RO ligation, a time at which up-regulation of
CD95 on T cells has not yet occurred.
Our findings that ligation of CD45RO/RB isoforms by
chA6 mAb results in a selective depletion of preexisting and
recently activated CD4 CD45RO/RBbright T cells, which
represent the memory/effector T cells compartment (17), is
consistent with results obtained in vivo. Treatment with
anti-CD45RB mAb in mice or with a pan–anti-CD45 mAb
in rats resulted in a reduction of the number of peripheral T
cells and ultimately in tolerance (11, 31, 32). In murine
models the selective elimination of CD45RBhigh cells by
anti-CD45RB mAb treatment promoted the survival of a T
reg cell subset within the CD45RBlow population that was
able to inhibit allograft rejection (10–12). Similarly, in ourIMMUNOMODULATORY EFFECTS OF AN ANTIHUMAN CD45RO/RB MAB | Gregori et al. 1302
study depletion of preexisting and newly activated CD4 
CD45RO/RBbright human T cells mediated by chA6 mAb
results in an increased percentage of CD4 A6low T cells (un-
published data), which may reset the T cell repertoire and
permit the induction of T reg cells. The A6  population
does contain memory T cells, because depletion of the A6 
cell subset from PBMCs of TT- or hepatitis B–sensitized in-
dividuals by murine A6 mAb resulted in considerably re-
duced responses to recall antigens (17).
ChA6 mAb selectively eliminates human CD4  memory
T cells, but the proportion of MP.58-66–specific CD8  T
cells generated with chA6 mAb was comparable to that ob-
served in controls, indicating that the CD8  T cell popula-
tion is unaffected. This finding is consistent with previous
observations that showed that murine A6 mAb did not alter
specific target-cell lysis mediated by cytotoxic T cells (17).
The molecular mechanism underlying this differential apop-
totic effect of chA6 mAb in CD4  and CD8  T cells re-
mains to be defined.
In addition to apoptosis, modulation of antigen-specific T
cell responses by chA6 mAb, with the induction of T reg 1
cells, is an important mode of action for this mAb. ChA6
mAb induces antigen-specific CD4  T reg cells that do not
acquire the CD4 CD25  T reg cell phenotype and do not
express FOXP3 (unpublished data), which is now recognized
as a critical factor in the differentiation and function of mouse
(33, 34) and human (35) CD4 CD25  T reg cells. ChA6
mAb induces T reg cells that display a T reg 1 cell phenotype
and function. So far, T reg 1 cells have been generated from
naive CD4  T cells in vitro either by using exogenous IL-10
and IFN-  (36) or vitamin D3 and dexamethasone (37) or by
repetitive stimulation with immature DC (38). Here, we
induced TT-specific T reg 1 cells from the memory CD4 
CD45RO/RBlow T cell compartment. Because chA6 mAb
depletes CD4 CD45RO/RBbright T cells, which represent
the effector/memory compartment, we suggest that chA6
mAb modulates central/memory cells, which are a part of the
CD4 CD45RO/RBlow T population, leading to the genera-
tion of antigen-specific T reg 1 cells.
Interestingly, chA6 mAb induces not only antigen-specific
CD4  T reg 1 cells but also antigen-specific CD8  T reg
cells. Studies in human CD8  T reg cells are still limited,
probably because of their poor proliferative capacity in vitro.
However, suppressor CD8 CD28  T cell lines can be gener-
ated in vitro (39) and have been isolated from peripheral
blood of successfully transplanted patients (40). Antigen-spe-
cific CD8  T cells generated with chA6 mAb express similar
levels of CD28 and lower levels of CD25  than do control
cells, indicating that chA6 mAb does not induce CD8 
CD28  T reg cells and has no effect on CD8 CD25  T reg
cells. ChA6-induced CD8  T reg cells share many similarities
with the CD8  T reg cells generated by plasmacytoid den-
dritic cells (DC2) (41) or by IL-10–treated DC (42). CD8  T
reg cells induced by these three different modalities are anergic
and suppress T cell responses. However, CD8  T reg cells in-
duced by DC2 did not suppress secondary responses of acti-
vated effector T cells (41), whereas chA6-induced CD8  T
reg cells are able to suppress proliferation of activated T cells of
the same specificity. Interestingly, CD8  T reg cells induced
by IL-10–treated DCs did not secrete IL-10 (43). Similarly,
we were unable to detect IL-10 production by chA6-induced
CD8  T reg cells (unpublished data). These findings suggest
that chA6 mAb induces antigen-specific CD8  T reg cells that
have phenotypical and functional properties similar to those of
IL-10–induced CD8  suppressor T cells.
To test the immunomodulatory effects of chA6 mAb in
vivo, we modified the model for human islet allograft rejec-
tion described by Shiroki et al. (44). In our model, injection
of freshly isolated allogeneic PBMCs at the time of the hu-
man islet transplantation in NOD/SCID mice resulted in the
rejection of the graft. Interestingly, three injections of chA6
mAb resulted in long-term survival of islet allograft in trans-
planted hu-PBL-NOD/SCID mice. This prolonged survival
was accompanied by a reduced infiltration of human lympho-
cytes. Similar to the effect observed in mouse islet allografts
with anti-CD45RB mAb treatment, three injections of chA6
mAb induced long-term engraftment in 50% of the hu-PBL-
NOD/SCID–recipient mice. This in vivo protective effect of
chA6 mAb was opposed to the inability of sirolimus to pro-
long graft survival in this model. Treatment for 30 d with the
Edmonton protocol resulted in a higher incidence of graft
survival. These data suggest that chA6 mAb administration
early after transplantation may induce long-term tolerance in
recipient mice, possibly through the apoptosis of activated
CD4  T cells and the induction of T reg 1 cells.
The mechanism by which chA6 mAb induces T reg 1
cells remains unclear and may involve both direct and indi-
rect effects on T cells. ChA6 mAb modulates T cell re-
sponses at nonapoptotic concentrations and increases the cal-
cium influx in T cells (unpublished data), indicating that it
can directly modulate T cell activation. In addition, it has
been demonstrated that CD45 suppresses JAK kinases and
negatively regulates cytokine receptor signaling including
those of IL-3, IL-4, and IFN-  (45). Therefore, ligation of
CD45RB/RO by chA6 mAb may also directly interfere
with signaling through cytokine receptors and modulation of
cytokine responses by T cells, allowing the induction of T
reg cells. Alternatively, chA6 mAb may act indirectly on an-
tigen-specific CD4  and CD8  T cells through modulation
of the APC that express the CD45RO/RB isoforms.
Different mechanisms, which are not mutually exclusive,
have been associated with tolerance induction: deleting mech-
anisms in which either allo- or autoreactive T cells are elimi-
nated and nondeleting mechanisms including anergy (46), im-
mune deviation, and active immunosuppression mediated by
T reg cells. Here we describe a new chimeric mAb, which se-
lectively depletes memory/effector CD4 CD45RO/RBbright
T cells, induces CD4  T reg 1 cells and CD8  T reg cells, and
prevents human islet allograft rejection in hu-PBL-NOD/
SCID mice. Therefore, it can be hypothesized that chA6 mAbJEM VOL. 201, April 18, 2005 1303
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may induce immunological tolerance in vivo by inducing
both clonal deletion and active immunosuppression.
MATERIALS AND METHODS
Generation of chimeric A6 antibody. ChA6 was generated by linking
the variable regions of mAb A6 (17), cloned by RT-PCR, with human  1
heavy chain– and human   light chain–constant regions. After transfection
into SP2/0 cells and selection of clones using G418 and methotrexate, the
antibody was purified by affinity chromatography on goat anti–human IgG
followed by size exclusion chromatography. Endotoxin was removed using
ActiClean Etox (Sterogene Bioseparations, Inc.). Final endotoxin levels
were below 30 pg/mg protein.
Mixed lymphocyte cultures and proliferation assay. Human periph-
eral blood was obtained from healthy donors in accordance with local ethi-
cal committee standards. PBMCs were separated by density-gradient cen-
trifugation over Lymphoprep (Amersham Biosciences). CD4  T cells
enriched by selective depletion of CD8, CD14, and CD19 cells (Oxoid
Linited) were used as responder, and CD3-depleted and irradiated (6,000
rad) cells were used as stimulators. CD4  T cells (105/well) were cultured in
RPMI 1640 medium (GIBCO BRL) supplemented with 100 U/ml pen-
icillin/streptomycin (Bristol-Myers Squibb), 10% heat-inactivated FCS
(Mascia Brunelli S.p.A.) in 96-well plates (Costar) for 5 d with CD3-
depleted cells (105/well) with or without chA6 or chimeric isotype control
mAbs (10  g/ml). To evaluate secondary responses, primary cultures were
carried on for 10 d; then cells were collected, washed, and plated in 96-well
plates with newly prepared stimulator cells with or without of chA6 mAb
(10  g/ml) for 2 d.
To analyze proliferation in response to polyclonal activation, CD4  T
cells (105/well) were cultured in 96-well plates precoated with anti-CD3
mAb (OKT3, Janssen Cilag, Ltd.) for 3 d in the presence or absence of
chA6 or chimeric isotype control mAbs (10  g/ml) with or without soluble
anti-CD28 mAb (1  g/ml) (BD Biosciences). To measure cell proliferation,
cultures were pulsed with [3H]thymidine during the last 16 h.
Apoptosis. After overnight incubation with chA6, anti-CD45RA (HI100,
BD Biosciences), anti-CD45RO (UCLH-1, BD Biosciences), or isotype
control, mAb cells were stained with annexin V–FITC (BD Biosciences)
and propidium iodide (50  g/ml, Sigma-Aldrich). Alternatively, cells were
stained with annexin V–FITC and anti–human IgG1 PE mAb (Sigma-
Aldrich). Analyses were performed using FACScan flow cytometer using
CellQuest software (BD Biosciences). To calculate the ED50 value, CD4  T
cells were stained, after overnight culture, with annexin V–FITC and CD2-
PE (BD Biosciences). Curve fitting and ED50 value calculations were per-
formed using Origin v7.5 SR2 software (OriginLab Corporation). To eval-
uate primary proliferative responses on annexin V  cell depletion, CD4  T
cells were incubated with chA6 mAb (10  g/ml) for 4 h at 37 C and de-
pleted using a dead cell removal kit (Miltenyi Biotec). Totally depleted or
annexin V–depleted CD4  T cells were used as responder cells, and irradi-
ated CD3-depleted cells were used as stimulators.
Western blot assay. Treated cells were resuspended in lysis buffer con-
taining 10 mM Tris-HCl, pH 7.2, 100 mM NaCl, 1 mM EDTA, 1% deoxy-
cholate acid, 1% Triton X-100, 0.1% SDS, 1 mM PMSF, 10  g/ml leu-
peptin, 10  g/ml peptstatin, and 0.23 U/ml aprotinin. The supernatants
were then centrifuged at 14,000 revolutions/min for 10 min at 4 C to re-
move lysosome and mitochondria. 40  g of protein were separated on SDS-
PAGE and transferred to a nitrocellulose membrane (Amersham Bio-
sciences). Blots were blocked 30 min at 37 C in PBS containing 10% nonfat
dried milk and incubated at 4 C with anti–caspase-3 (anti-CCP32), anti–cas-
pase-8 (1C12, Cell Signaling Technology), and anti-caspase-9 (Asp 315, Cell
Signaling Technology) mAbs. Detection was achieved with the appropriate
secondary antibodies coupled to horseradish peroxidase followed by en-
hanced chemiluminescence Western blotting (Amersham Biosciences).
Mitochondrial permeability assay. CD4  T cells were incubated for 2 h
with 5  g/ml chA6 or isotype control mAbs in the presence of 15  g/ml of
cross-linking goat anti–human IgG (F[ab ]2). Cells were washed and resus-
pended in culture medium without FCS containing 20 nM of 3,3 -dihexyl-
oxacarbocyanine iodide (DiOC6[3]) (Molecular Probes). After incubation
for 20 min, cells were washed, resuspended in PBS, and analyzed on
a FACSCalibur (BD Biosciences). The mitochondrial accumulation of
DiOC6(3) was used to assess   m in the mitochondria.
Antigen-specific responses. For in vitro induction of effector cells spe-
cific for TT, PBMCs depleted of CD8  and CD19  cells (2   106 cells/
well) were cultured in 24-well plates with 5  g/ml TT (Calbiochem) with
or without chA6 mAb (10  g/ml) in X-VIVO 15 (Cambrex BioScience
Inc.) supplemented with 100 U/ml penicillin/streptomycin, 5% heat-inac-
tivated human serum (Cambrex BioScience, Inc.). After 10 d, the bulk
populations were restimulated with autologous irradiated (6,000 rad) CD3-
depleted cells pulsed with TT with or without chA6 mAb (10  g/ml). The
responder populations were analyzed after the second stimulation for prolif-
eration: 104 T cell lines were stimulated with 5   104 autologous irradiated
monocytes with or without TT, in the absence of chA6 mAb for 2 d and
pulsed with [3H]thymidine during the last 16 h. For suppressor assay, TT-
specific T cell lines generated without chA6 mAb were cocultured with in-
creased amounts of TT-specific T cell lines generated in the presence of
chA6 mAb with TT-pulsed and nonpulsed autologous irradiated monocytes
in the absence of chA6 mAb. After 48 h of culture, IFN-  was quantified in
culture supernatants by two-site ELISA.
For in vitro induction of effector cells specific for influenza peptide
MP.58-66, CD8-enriched T cells from HLA-A*0201  healthy donors
were seeded (2   106/well) in 24-well plates with 10  g/ml peptide
MP.58-66, with or without chA6 mAb (10  g/ml). After 10 d, responder
CD8  T cells were restimulated with autologous irradiated monocytes
pulsed with the MP.58-66 peptide. The responder populations were ana-
lyzed after the second stimulation for IFN-  release against peptide-pulsed
and nonpulsed T2 cells, which are HLA-A*0201  APC 8   103 T cell lines
were stimulated with 2   104 irradiated (10,000 rad) T2 cell lines. At the
end of each round of stimulation with the MP.58-66 peptide, cells (0.5–1  
106) were stained with T cell receptor V 17-specific mAb.
FACS analysis. Anti-CD4, -CD8, -CD25, and -CD28 mAbs directly cou-
pled with FITC and PE were purchased from BD Bioscience. Cells were incu-
bated with the indicated mAbs for 20 min at 4 C in PBS plus 2% FCS, washed
twice, and analyzed by FACS using CELLQuest software (BD Biosciences).
Cytokine secretion. TT-specific CD4  T cells (5   103) were stimulated
with 2   104 autologous irradiated monocytes with or without 5  g/ml TT.
Supernatants were collected after 24 h for IL-2, after 48 h for IL-4 and
IFN- , and after 72 h for IL-10 and TGF- . Levels of IL-2, IL-4, IL-10, and
IFN-  were determined by capture ELISA according to the manufacturer’s
instructions (BD Bioscience). Levels of TGF-  in acidified supernatants were
determined by capture ELISA according to the manufacturer’s instructions
(R&D Systems). The limits of detection were as follows: IL-2: 20 pg/ml; IL-4:
20 pg/ml; IL-10: 20 pg/ml; IFN- : 60 pg/ml; TGF- : 60 pg/ml.
Mice. NOD/SCID female mice were purchased from Charles River Lab-
oratories. All mice were kept under specific-pathogen–free conditions. All
animal care procedures were performed according to protocols approved by
the HSR Institutional Animal Care and Use Committee, IACUC 156.
Blood glucose level was quantified using Glucometer Elite system (Bayer
AG). Diabetes was induced in NOD/SCID mice by intravenous injection
of streptozotocin (Sigma-Aldrich) at 180 mg/kg. A diagnosis of diabetes was
made after two consecutive glucose measurements  350 mg/dl.
Islet preparations and transplantation. Pancreases were obtained from
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tion. Islets were isolated according to a modification of the automated
method (47). The purified islets were cultured in M199 medium (Seromed
Biochrom KG) supplemented with 10% FCS, 1% l-glutamine, 100 U/ml
penicillin, and 100  g/ml streptomycin and incubated at 30 C in 5% CO2
and 95% humidified air. Mice were anesthetized with an intraperitoneal in-
jection of avertin, and aliquots of 1,500 IE of human islets were transplanted
under the kidney capsule of recipient diabetic NOD/SCID mice as previ-
ously described (48). After transplantation, recipient NOD/SCID mice were
injected intraperitoneally with 50   106 freshly isolated allogeneic PBMCs.
Treatments of transplanted mice. Hu-PBL-NOD/SCID transplanted
mice were treated at days 0, 3, and 5 with chA6 mAb 1 mg/kg subcuta-
neously; or with the Edmonton protocol: anti-IL-2R mAbs (Zenapax,
Roche), 200  g/mouse, administered intraperitoneally at day 0 and at day 4
after transplantation; sirolimus (Rapamune, Wyeth-Ayerst Research) di-
luted in peanut oil (Sigma-Aldrich) and administered once daily at 1 mg/kg
by gavage from days 0 to 30 after transplantation, and tacrolimus (Prograf,
Fujisawa) diluted in saline solution and administered once daily at 0.3 mg/
kg intraperitoneally from days 0 to 30 after transplantation; or with siroli-
mus alone once daily at 1 mg/kg by gavage from days 0 to 30 after trans-
plantation. Control mice were treated with saline solution or with IgG1-
purified mAb (Vinci-Biochem).
Histological analysis. Kidneys containing human islet grafts were snap-
frozen in Tissue Tek (Miles Laboratories, Inc.) and stored at  70 C. Frozen
sections, 5  m thick, were stained with biotinylated mAb against human
insulin followed by streptavidin-peroxidase conjugate. Diaminobenzidine
(DakoCytomation) was used as chromogen, and hematoxylin as was used as
counterstain. Lymphocyte infiltration of the grafts was evaluated on hema-
toxylin and eosin–stained frozen sections.
Statistical analysis. All analyses for statistically significant differences were
performed with the Student’s t test or nonparametric Wilcoxon test. p-val-
ues  0.05 were considered significant.
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